SenoRx Breast Biopsy System Available For Use With MRI

Aliso Viejo, CA - SenoRx Inc. announced that over 30 healthcare institutions are now capable of performing MRI-guided biopsy procedures using the EnCor Multi-Modality, Modular Biopsy System. Lloyd H. Malchow, president and CEO of SenoRx, commented, "The EnCor system can be easily moved to perform diagnosis in any patient venue and with any of the preferred imaging modalities." The MRI breast biopsy segment is rapidly growing and is an excellent opportunity for SenoRx. EnCor is the next-generation state-of-the-art, fully automated system and the first breast biopsy system to offer the benefits of both open and closed automated tissue collection. EnCor received FDA 510(k) clearance on Aug. 19, 2004.

EnCor is a fully programmable, automated, multi-modality, modular breast biopsy system available representing the next generation of technology in breast disease diagnosis. SenoRx completed over 20,000 cases prior to full commercial launch of EnCor in November 2005 and has installed over 170 systems in healthcare institutions in the U.S. and Canada.

Today, over 1,000 healthcare institutions in the United States use at least one of five commercially available SenoRx products, which the company began marketing in 2002. SenoRx currently has an annualized revenue run rate of $23M and had 2005 revenue of approximately $19.3MM. Additionally, SenoRx has three new 510(k)-cleared products scheduled to launch in the next 18 to 24 months.

SOURCE: SenoRx Inc.